Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure

Fedratinib is an oral, selective Janus kinase 2 (JAK2) inhibitor. The phase II JAKARTA2 study assessed fedratinib in patients with intermediate‐ or high‐risk myelofibrosis (MF) who were resistant or intolerant to prior ruxolitinib per investigator assessment. Patients received fedratinib 400 mg/day...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Am J Hematol
Main Authors: Harrison, Claire N., Schaap, Nicolaas, Vannucchi, Alessandro M., Kiladjian, Jean‐Jacques, Jourdan, Eric, Silver, Richard T., Schouten, Harry C., Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek, Srdan, Rose, Shelonitda, Shen, Juan, Berry, Tymara, Brownstein, Carrie, Mesa, Ruben A.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2020
Assuntos:
Research Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7317815/
https://ncbi.nlm.nih.gov/pubmed/32129512
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.25777
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares